Setback for UK pharma as government sets unexpectedly high VPAG payback rate in 2025
The UK Department of Health and Social Care (DHSC) has announced its anticipated 2025 headline payback rate for new medicines…
All articles by Alex Watt
Alex Watt
-
-
Exploring drug shortages in European markets: the causes, analysis, and response
Since 2023, the pharmaceutical industry operating in Europe has faced an unprecedented challenge related to drug shortages. Previously, shortages were…
-
Keytruda and Opdivo: a decade review
PD-1 inhibitors have become a paramount achievement in the oncology space and have revolutionised cancer treatment over the last decade.…
-
Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy
In December 2023, Vertex (US) and CRISPR Therapeutics’s (Switzerland and US) Casgevy (exagamglogene autotemcel) was approved in the US for…
-
Ukraine: a market access review over two years of war
Since the Russian invasion of Ukraine in early 2022, the Ukrainian budget has prioritised national security and defence. However, other…
-
The privileged status of orphan medicines in Germany
In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question…
-
Defining the HTA landscape for France and Germany: 2019–2023
Health technology assessments (HTA), defined by the World Health Organization (WHO) as “the systematic evaluation of properties, effects and/or impacts…
-
EU access to oncology medicines lags behind in the Netherlands
Recently, a study published in the National Library of Medicine compared market access trends in Belgium, France, Hungary, Italy, Switzerland,…
-
Insights from ISPOR Europe 2023: Copenhagen
Recently back from the beautiful city of Copenhagen, it was an honour to see some of the brightest minds in…
-
Semaglutide: a price and HTA comparison between US and top European markets
The US is known for having higher list prices for drugs than other high-income countries. But these higher prices have…